Lannett Co Inc: (AMEX: LCI)

$12.28

0.42 (3.54%)

Volume 158,709

May 15 03:37 PM ET

Zacks Rank: 2-Buy

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		11.72 - 12.40
	
		52wk Low - High
		3.72 - 12.47
	
		Previous Close
		11.86
	
		Avg. Volume
		148,326
	
		Industry
		MED-DRUGS
	
		Market Cap
		336.70 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.54
	
		PE (Forward)
		31.84
	
		Current Year Est.
		0.37
	
		Quarterly Earnings ESP 
		14.29%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		2
Buy

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Outperform
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		86 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/10/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            31.84
                        
                            PEG Ratio
                            1.59
                        
                            Current Year Est.
                            0.37
                        
                            Current Quarter Estimate
                            0.07
                        
                            Most Accurate Estimate
                            0.08
                        
                            Earnings ESP 
                            14.29%
                        
                            Next Earnings Report Date
                            09-05-2013
                        
                            EPS Last Year
                            0.37
                        
                            Expected Earnings Growth
                            20.00%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies.   
Full LCI Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
LCI Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (06/2013)	Next Year (06/2014)
Average Estimate	0.07	0.08	0.37	0.39
Number of Estimates	4	2	4	4
Low Estimate	0.02	0.07	0.21	0.27
High Estimate	0.10	0.08	0.44	NA
Year Ago EPS	0.06	0.07	0.15	0.37
EPS Growth	12.50%	7.14%	148.33%	4.70%

More LCI Estimates

Average Earnings Estimates for LCI

EPS Growth for LCI

Industry Analysis

Name	Symbol	Previous Close
LANNETT INC	LCI	11.86
CATALYST PHARMA	CPRX	0.90
JAZZ PHARMACEUT	JAZZ	59.00
SALIX PHARM-LTD	SLXP	59.29
SANTARUS INC	SNTS	21.02
USANA HLTH SCI	USNA	60.62
BIOCRYST PHARMA	BCRX	1.81
CELL THERAPEUT	CTIC	1.19
CUBIST PHARM	CBST	48.77
ELAN CP PLC ADR	ELN	11.45

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Isis Gets $3.5M Milestone Payment

May 14, 2013

NPS Pharma Incurs Narrower 1Q Loss

May 14, 2013

Narrower-than-Expected Loss at Supernus

May 14, 2013

Setback for Endo Health on Opana ER

May 13, 2013

Pacira Reports Wider Loss

May 10, 2013

Narrower-Than-Expected Loss at Rigel Pharma

May 09, 2013

Wider-than-Expected Loss at Avanir

May 09, 2013

Earnings Beat at Endo Health, Sales Slip

May 08, 2013

More LCI Zacks Commentary

Financials

EPS TTM	0.37
Sales	123
Net Income	11
Price/Earnings	32.05
Price/Book	2.72
Price/Cash Flow	33.99
Price/Sales	2.30

More LCI Financials

News

Lannett Reports Fiscal 2013 3Q Financial Results - Close-Up Media

May 12, 2013

Lannett Reports Fiscal 2013 Third Quarter Financial Results - Close-Up Media

May 12, 2013

Lannett Company, Inc.Corporate Event Announcement Notice - Wall Street Horizon

May 9, 2013

Lannett Company, Inc.Corporate Event Announcement Notice - Wall Street Horizon

May 8, 2013

Lannett Raises Revenue Guidance - Earningswhispers Earnings Guidance

May 8, 2013

Lannett Reports Record Fiscal 2013 Third Quarter Financial Results - Businesswire

May 8, 2013

The Best Performing Low Risk Stocks of the Year So Far - Kapitall

May 8, 2013

LCI, ETP, RWC, MBLX, AVNR, HALL Expected To Be Down After Next Earnings Releases - M2

May 7, 2013

See All News Stories on LCI

Broker Recommendations

Current ABR	1.00
ABR (Last Week)	1.00
# of recs in ABR	4
Average Target Price	12.19
Industry Rank by ABR	86 out of 265
Rank in Industry	6 out of 91

More LCI Broker Recommendations

Day Low - High	11.72 - 12.40
52wk Low - High	3.72 - 12.47
Previous Close	11.86
Avg. Volume	148,326
Industry	MED-DRUGS
Market Cap	336.70 M
Div - Yield	0.00 - 0.00
Beta	0.54
PE (Forward)	31.84
Current Year Est.	0.37
Quarterly Earnings ESP	14.29%

PE (Forward)	31.84
PEG Ratio	1.59
Current Year Est.	0.37
Current Quarter Estimate	0.07
Most Accurate Estimate	0.08
Earnings ESP	14.29%
Next Earnings Report Date	09-05-2013
EPS Last Year	0.37
Expected Earnings Growth	20.00%

Username: Password:

Remember me [?]

Lannett Co Inc: (AMEX: LCI)

$12.28

0.42 (3.54%)

Volume 158,709

May 15 03:37 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-DRUGS

Zacks Commentary

Financials

News

Broker Recommendations